Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H21NO |
Molecular Weight | 267.3654 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(C1CCNCC1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=ZMISODWVFHHWNR-UHFFFAOYSA-N
InChI=1S/C18H21NO/c20-18(15-7-3-1-4-8-15,16-9-5-2-6-10-16)17-11-13-19-14-12-17/h1-10,17,19-20H,11-14H2
Molecular Formula | C18H21NO |
Molecular Weight | 267.3654 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Azacyclonol (aka gamma-pipradrol) is an ataractive agent; a compound which diminished hallucinations in psychotic individuals. It is sometimes referred to as a tranquilizer or antipsychotic, though it does not actually possess these properties. It was used in Europe during the 1950's for treatment of schizophrenia; likely to reduce the psychedelic effects of LSD and mescaline. However, it had mixed clinical effectiveness and did not gain widespread adoption and was eventually discontinued. Azacyclonol was sold under several trade names: Ataractan, Calmeran, Frenoton, Frenquel and Psychosan.
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Azacyclonol (frenquel) hydrochloride in the treatment of chronic schizophrenia; a double-blind, controlled study. | 1957 Sep 28 |
|
Intravenous use of azacyclonol. | 1958 May |
|
Azacyclonol in chronic schizophrenia. | 1959 Sep 1 |
|
[Azacyclonol (Frenquel). Uses and results]. | 1960 Oct |
|
THE HYPOGLYCAEMIC EFFECT OF AZACYCLONOL AND ITS MECHANISM. | 1963 Oct 1 |
|
The effect of rifampin administration on the disposition of fexofenadine. | 2001 Mar |
|
Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. | 2006 Aug |
|
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. | 2006 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13383414
Chronic Schizophrenics were treated for four weeks with daily oral doses of 20 mg Frenquel to control the hallucinogenic effects of LSD. Twenty-one of thirty-eight patients showed definite improvements, while seven more showed doubtful-improvement. Frenquel was also used in oral doses of up to 400 mg daily.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:17 GMT 2023
by
admin
on
Fri Dec 15 15:08:17 GMT 2023
|
Record UNII |
2MMR990PEM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2MMR990PEM
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
m575
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
3680
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
100000086907
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
115-46-8
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
655
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
DTXSID2045280
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
SUB05628MIG
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
15723
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
C100095
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
AZACYCLONOL
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
204-092-5
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL127508
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY | |||
|
C76502
Created by
admin on Fri Dec 15 15:08:17 GMT 2023 , Edited by admin on Fri Dec 15 15:08:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|